Tests ivonescimab with chemotherapy for advanced pleural mesothelioma
Tests ivonescimab plus chemotherapy as first treatment in adults with advanced pleural mesothelioma.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Key facts
- Where
- Chengdu and Shanghai, ChinaSee the 3 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07885319, who can take part
Where in China
- West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Shanghai Chest HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT07885319
- Record updated
- 2 November 2026
- Original description
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.Read full original descriptionShow less
A Phase 1b/2, Open-Label, Multicenter, Single-Arm Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Phase 1b evaluates the candidate recommended Phase 2 dose (RP2D), followed by Phase 2 evaluation at the confirmed RP2D.
Inclusion: Age 18 to 75 years; Histologically confirmed advanced or metastatic malignant pleural mesothelioma not amenable to surgery; No prior systemic anticancer therapy for advanced disease; ECOG PS 0-1; At least one measurable lesion according to modified RECIST (mRECIST); Adequate organ function for study treatment; Patients with asymptomatic or stable brain metastases are eligible; Able to understand the study, provide written informed consent, and comply with study procedures.
Exclusion: Active autoimmune disease requiring systemic treatment or other contraindications to immunotherapy; Uncontrolled hypertension, significant bleeding risk, or other contraindications to antiangiogenic therapy; Active interstitial lung disease or noninfectious pneumonitis; Active infection requiring systemic treatment; Other active malignancies requiring anticancer treatment; Severe uncontrolled medical conditions that may interfere with study treatment; Pregnant or breastfeeding women.